Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma - Chiu, Tai-Jan; Huang, Tai-Lin; Chien, Chih-Yen; Huang, Wan-Ting; Li, Shau-Hsuan (World journal of surgical oncology, 2024)
Keywords: Adult; Aged; Aged, 80 and over; Albumin; Biomarkers, Tumor - blood; Calcium; Drug therapy; Female; Follow-Up Studies; Head and neck cancer; Head and Neck Neoplasms - blood; Head and Neck Neoplasms - complications; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - immunology; Head and Neck Neoplasms - pathology; Health aspects; Humans; Hypercalcemia; Hypercalcemia - blood; Hypercalcemia - drug therapy; Hypercalcemia - etiology; Hypoalbuminemia - complications; Hypoalbuminemia - etiology; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - therapeutic use; Male; Metastasis; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - pathology; Patient outcomes; Physiological aspects; Prognosis; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Retrospective Studies; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - blood; Squamous Cell Carcinoma of Head and Neck - drug therapy; Squamous Cell Carcinoma of Head and Neck - immunology; Squamous Cell Carcinoma of Head and Neck - pathology; Survival Rate; Taiwan; Albumin; Head and neck cancer; Squamous cell carcinoma; Immune checkpoint inhibitors; Calcium